Primary Care Update Mark Ebell

We are really excited to introduce our new co-host, Dr. Kate Rowland, an Associate Professor in the Department of Family Medicine at Rush University in Chicago. We have been teaching with Kate for a long time in our in-person courses, and it's great to have her on board for the podcast. This week we talk about a new study from Oxford University finding a clear benefit for inhaled steroids in patients newly diagnosed with COVID-19. Kate discusses changes (good ones!) in regulations around MAT, Henry has good news about managing 5th metatarsal fractures, and John closes with data on the safety of mRNA vaccines in pregnancy. And the quiz!

This week, Mark reports the first study looking at the duration of symptoms with mild COVID in healthcare workers (more than you think) compared to those without COVID. Then Henry looks at the same thing in hospitalized COVID patients compared to those with other respiratory infections in the US and UK, and John tells us the true rate of anaphylaxis with vaccines.

This week we discuss a huge and really important meta-analysis of SGLT-2 inhibitors (flozins) and GLP-1 agonists (tides). Also, a good guideline on Lyme disease diagnosis and treatment, and a novel approach to treating migraine.

This week: low-carb diets for patients with T2DM, managing patients with chronic back pain, and reinfection rates in patients with COVID. Plus the quiz, and a reality TV recommendation.

This week, Mark, Henry and guest POET Kate Rowland from Rush Medical College discuss: newer agents to treat diabetes,  a new medication for migraine prevention, and antidepressants for pain in patients with back pain or DJD.

This week, we will discuss a potpourri of COVID studies: a large propensity score matched study of thromboprophylaxis in hospitalized patients, novel use of colchicine for COVID-19, and mortality associated with mutant SARS-CoV-2 strains.